Company Overview
Snapshot
Founded in October 2012 by Boaz Harari and Prof. Menahem Neuman, FEMSelect operates with 11–50 employees. The company has raised $16.89M across 7 funding rounds from 14 investors. In October 2022, FEMSelect secured Series B financing with New Age Ventures as a lead investor.
Business overview
FEMSelect is a Health Tech & Life Sciences company focused on developing innovative solutions for women's health. Its core product, EnPlace, is a minimally invasive and mesh-free system designed for pelvic floor ligament fixation. The EnPlace procedure, which takes approximately 30 minutes, utilizes a patented delivery system for precise anchor deployment through the vaginal wall, securing it to the pelvic floor ligament for stabilization. The device, which is FDA cleared and CE marked, combines a Nitinol-based anchor, surgical sutures, and an attachment method, eliminating the need for deep dissection or mesh. FEMSelect serves the medical devices market, targeting doctors, surgeons, and hospitals with treatments for pelvic organ prolapse.
Strategic signal
In June 2023, FEMSelect was highlighted for its innovative pelvic floor solutions, signaling a continued focus on improving women's quality of life through advanced medical technology. This indicates the company's ongoing commitment to market penetration and the strategic validation of its EnPlace system within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is FEMSelect's core product?
- FEMSelect's core product is EnPlace, a minimally invasive and mesh-free system designed for pelvic floor ligament fixation. The system uses a Nitinol-based anchor and surgical sutures, delivered through a patented system.
- When was FEMSelect founded and by whom?
- FEMSelect was founded in October 2012 by co-founders Boaz Harari and Prof. Menahem Neuman.
- Has FEMSelect received any significant regulatory clearances?
- Yes, FEMSelect's EnPlace device is FDA cleared and CE marked, indicating it meets regulatory standards for safety and efficacy in key markets.
- What was a notable funding event for FEMSelect?
- In October 2022, FEMSelect raised Series B financing, with New Age Ventures leading the round.
- What was a key commercial milestone for FEMSelect?
- In November 2021, FEMSelect announced CMS reimbursement for its minimally invasive pelvic organ prolapse repair procedure, which is crucial for market access and patient adoption.